Hutchison MediPharma Limited - Product Pipeline Review - 2013 - New Market Research Report

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Logo

Boston, MA -- (SBWire) -- 08/06/2013 --Global Market Direct's pharmaceuticals report, "Hutchison MediPharma Limited - Product Pipeline Review - 2013" provides data on the Hutchison MediPharma Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Hutchison MediPharma Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Hutchison MediPharma Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Hutchison MediPharma Limited - Brief Hutchison MediPharma Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hutchison MediPharma Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hutchison MediPharma Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hutchison MediPharma Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Evaluate Hutchison MediPharma Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Hutchison MediPharma Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Hutchison MediPharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Hutchison MediPharma Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Hutchison MediPharma Limited and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Hutchison MediPharma Limited - Product Pipeline Review - 2012
- Alchemia Limited - Product Pipeline Review - 2013
- CSL Limited - Product Pipeline Review - 2013
- Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2013
- Lupin Limited - Product Pipeline Review - 2013
- Daiichi Sankyo Company, Limited - Product Pipeline Review - 2013
- Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2013
- Aurigene Discovery Technologies Limited - Product Pipeline Review - 2013
- Mundipharma International Limited - Product Pipeline Review - 2013
- Teijin Pharma Limited - Product Pipeline Review - 2013

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/294801